Abstract
Alopecia areata (AA) is a complication of biologic therapy with several anti-tumor necrosis factor (TNF) inhibitors and efalizumab for the treatment of various autoimmune diseases. We report the case of a 51-year-old woman who developed AA universalis while undergoing treatment with daclizumab, an immunosuppressive biologic therapy, administered for treatment of inflammatory ocular disease. Although immunomodulatory agents that function by interfering with T helper cell stimulation are expected to impede autoimmune-related processes, we believe that daclizumab may be causally related to the development of AA.
| Original language | English (US) |
|---|---|
| Journal | Cutis |
| Volume | 93 |
| Issue number | 5 |
| State | Published - Jan 1 2014 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Dermatology
Cite this
}
Alopecia areata universalis complicating daclizumab therapy for uveitis. / Rosenstein, Adam K.; Machler, Brian C.; Rosenstein, Elliot.
In: Cutis, Vol. 93, No. 5, 01.01.2014.Research output: Contribution to journal › Article
TY - JOUR
T1 - Alopecia areata universalis complicating daclizumab therapy for uveitis
AU - Rosenstein, Adam K.
AU - Machler, Brian C.
AU - Rosenstein, Elliot
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Alopecia areata (AA) is a complication of biologic therapy with several anti-tumor necrosis factor (TNF) inhibitors and efalizumab for the treatment of various autoimmune diseases. We report the case of a 51-year-old woman who developed AA universalis while undergoing treatment with daclizumab, an immunosuppressive biologic therapy, administered for treatment of inflammatory ocular disease. Although immunomodulatory agents that function by interfering with T helper cell stimulation are expected to impede autoimmune-related processes, we believe that daclizumab may be causally related to the development of AA.
AB - Alopecia areata (AA) is a complication of biologic therapy with several anti-tumor necrosis factor (TNF) inhibitors and efalizumab for the treatment of various autoimmune diseases. We report the case of a 51-year-old woman who developed AA universalis while undergoing treatment with daclizumab, an immunosuppressive biologic therapy, administered for treatment of inflammatory ocular disease. Although immunomodulatory agents that function by interfering with T helper cell stimulation are expected to impede autoimmune-related processes, we believe that daclizumab may be causally related to the development of AA.
UR - http://www.scopus.com/inward/record.url?scp=84900509482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900509482&partnerID=8YFLogxK
M3 - Article
VL - 93
JO - Cutis
JF - Cutis
SN - 0011-4162
IS - 5
ER -